Imprimis Pharmaceuticals Inc Share Price Nasdaq
Stocks
US45323A2015
Pharmaceuticals
| Market Cap | 160.02Cr 139.91Cr 129.06Cr 118.64Cr 224.8Cr 15TCr 228.64Cr 1.54TCr 604.56Cr 7.53TCr 600.95Cr 587.78Cr 26TCr | P/E 2026 * |
173x | P/E 2027 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise Value | 160.02Cr 139.91Cr 129.06Cr 118.64Cr 224.8Cr 15TCr 228.64Cr 1.54TCr 604.56Cr 7.53TCr 600.95Cr 587.78Cr 26TCr | EV / Sales 2026 * |
4.59x | EV / Sales 2027 * | 3.1x |
| Free-Float |
84.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Imprimis Pharmaceuticals Inc
| 1 day | +0.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 53 | 17/12/2011 |
Andrew Boll
PSD | President | 43 | 21/08/2025 |
Brett Burrell
CMP | Compliance Officer | - | 01/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Baum
CHM | Chairman | 53 | 19/08/2021 |
Perry Sternberg
BRD | Director/Board Member | 57 | 31/03/2022 |
Adrienne Graves
BRD | Director/Board Member | 71 | 26/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.83% | +11.11% | - | - | 154.21Cr | |
| +0.35% | -4.87% | +49.87% | +157.34% | 1,02800Cr | |
| -2.69% | -6.22% | +59.19% | +54.51% | 61TCr | |
| +0.44% | -3.41% | +30.97% | +79.48% | 43TCr | |
| +0.98% | -1.40% | +29.49% | +21.76% | 32TCr | |
| -0.34% | -3.10% | +27.00% | +43.60% | 28TCr | |
| +1.63% | -11.76% | +19.72% | +21.72% | 26TCr | |
| +3.39% | +2.29% | -23.68% | -37.83% | 22TCr | |
| +0.86% | -2.63% | +22.50% | +57.55% | 19TCr | |
| +1.28% | -3.03% | +20.76% | +70.62% | 16TCr | |
| Average | +0.67% | -4.60% | +26.20% | +52.08% | 38.87TCr | |
| Weighted average by Cap. | +0.19% | -4.85% | +35.86% | +76.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 35Cr 30Cr 28Cr 26Cr 49Cr 3.35TCr 50Cr 335.51Cr 131.64Cr 1.64TCr 130.86Cr 127.99Cr 5.65TCr | 52Cr 45Cr 42Cr 38Cr 72Cr 4.96TCr 74Cr 496.5Cr 194.81Cr 2.43TCr 193.65Cr 189.4Cr 8.36TCr |
| Net income | 98.1L 85.77L 79.12L 72.73L 1.38Cr 94Cr 1.4Cr 9.45Cr 3.71Cr 46Cr 3.68Cr 3.6Cr 159.03Cr | 9.29Cr 8.12Cr 7.49Cr 6.89Cr 13Cr 894.16Cr 13Cr 89Cr 35Cr 437.04Cr 35Cr 34Cr 1.51TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
